Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates

BACKGROUND: Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only currently available anabolic agent expected to be effective for GIOP...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Springerplus
Главные авторы: Seno, Takahiro, Yamamoto, Aihiro, Kukida, Yuji, Hirano, Aiko, Kida, Takashi, Nakabayashi, Amane, Fujioka, Kazuki, Nagahara, Hidetake, Fujii, Wataru, Murakami, Ken, Oda, Ryo, Fujiwara, Hiroyoshi, Kohno, Masataka, Kawahito, Yutaka
Формат: Artigo
Язык:Inglês
Опубликовано: Springer International Publishing 2016
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4940355/
https://ncbi.nlm.nih.gov/pubmed/27462504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-2704-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы